Ország: Hollandia
Nyelv: holland
Forrás: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
TRAVOPROST
Alfred Tiefenbacher (GmbH & Co. KG) Van-der-Smissen- Strasse 1 22767 HAMBURG (DUITSLAND)
S01EE04
TRAVOPROST
Oogdruppels, oplossing
BOORZUUR (E 284) ; MACROGOLGLYCEROLHYDROXYSTEARAAT ; MANNITOL (D-) (E 421) ; NATRIUMCHLORIDE ; NATRIUMHYDROXIDE (E 524) ; POLIDRONIUM CHLORIDE ; PROPYLEENGLYCOL (E 1520) ; WATER, GEZUIVERD ; ZOUTZUUR (E 507), BOORZUUR (E 284) ; MACROGOLGLYCEROLHYDROXYSTEARAAT ; MANNITOL (D-) (E 421) ; NATRIUMCHLORIDE ; NATRIUMHYDROXIDE (E 524) ; POLYQUATERNIUM-1 ; PROPYLEENGLYCOL (E 1520) ; WATER, GEZUIVERD ; ZOUTZUUR (E 507),
Oculair gebruik
Travoprost
Hulpstoffen: BOORZUUR (E 284); MACROGOLGLYCEROLHYDROXYSTEARAAT; MANNITOL (D-) (E 421); NATRIUMCHLORIDE; NATRIUMHYDROXIDE (E 524); POLYQUATERNIUM-1; PROPYLEENGLYCOL (E 1520); WATER, GEZUIVERD; ZOUTZUUR (E 507);
2015-11-18
1 PACKAGE LEAFLET: INFORMATION FOR THE USER TRAELB 40 MICROGRAM/ML OOGDRUPPELS, OPLOSSING Travoprost READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet, See section 4. WHAT IS IN THIS LEAFLET 1 What Traelb is and what it is used for 2. What you need to know before you use Traelb 3. How to use Traelb 4. Possible side effects 5. How to store Traelb 6. Contents of the pack and other information 1. WHAT TRAELB IS AND WHAT IT IS USED FOR Traelb CONTAINS TRAVOPROST, one of a group of medicines called PROSTAGLANDIN ANALOGUES . It works by reducing the pressure in the eye. It may be used on its own or with other drops e.g. beta-blockers, which also reduce pressure. Traelb IS USED TO REDUCE HIGH PRESSURE IN THE EYE IN ADULTS, ADOLESCENTS AND CHILDREN FROM 2 MONTHS OLD ONWARD. This pressure can lead to an illness called GLAUCOMA. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE TRAELB DO NOT USE TRAELB IF YOU ARE ALLERGIC to travoprost or any of the other ingredients of this medicine (listed in section 6). Ask your doctor for advice if this applies to you. WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before using Traelb Traelb MAY INCREASE the length, thickness, colour and/or number of your EYELASHES . Changes in the eyelids including unusual hair growth or in the tissues around the eye have also been observed. Traelb may CHANGE THE COLOUR OF YOUR IRIS (the coloured part of your eye). This change may be permanent. A change in the colour of the skin around the eye may also occur. If you have had CATARACT SURGERY , talk to your doctor be Olvassa el a teljes dokumentumot
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Traelb 40 microgram/ml oogdruppels, oplossing 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of solution contains 40 micrograms of travoprost. Excipient(s) with known effect: Each mL of solution contains 10 microgram ofpolidronum chloride. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Eye drops, solution. (Eye drops) Clear, colourless solution. pH 6.3 to 7.3; osmolality 265 - 320 mOsmol/kg 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Use in adults, including elderly population _ The dose is one drop of Traelb in the conjunctival sac of the affected eye(s) once daily. Optimal effect is obtained if the dose is administered in the evening. Nasolacrimal occlusion or gently closing the eyelid after administration is recommended. This may reduce the systemic absorption of medicinal products administered via the ocular route and result in a decrease in systemic adverse reactions. If more than one topical ophthalmic medicinal product is being used, the medicinal products must be administered at least 5 minutes apart (see section 4.5). If a dose is missed, treatment should be continued with the next dose as planned. The dose should not exceed one drop in the affected eye(s) daily. When substituting another ophthalmic antiglaucoma medicinal product with travoprost eye drops, the other medicinal product should be discontinued and travoprost eye drops should be started the following day. _Patients with hepatic and renal impairment _ Travoprost has been studied in patients with mild to severe hepatic impairment and in patients with mild to severe renal impairment (creatinine clearance as Olvassa el a teljes dokumentumot